Tonghua Dongbao Pharmaceutical will invest 367.2 million yuan ($59.21 million) to build a new facility to make insulin APIs, Reuters reported, citing a Chinese text press release from the country. The company, which already makes bulk insulin, needs the capacity to meet growing demand.
Takeda Pharmaceutical has offered $2.2 billion to settle all U.S. claims linked to its diabetes drug Actos as it battles thousands of cases and stretches legal resources even with some verdicts favorable, a report said April 1.
Glenmark's marketing of a couple of diabetes generics in the United States continues to fluctuate like a yo-yo on a string. Now the India drugmaker can return the drugs to market until April 28.
Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.
U.S.-based Orgenesis has been contracting for the sophisticated manufacturing capabilities of MaSTherCell as it moves to clinical trials with its process to reprogram human liver cells in people with Type 1 diabetes into insulin-producing cells. Now it will own them.
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression.
A group of researchers at Cornell says it engineered a human probiotic that also had a similar effect in controlling blood glucose levels in rat models for the disease. And a biotech has already snagged the license on this work as they set the stage to try it in humans.
A transatlantic team of researchers says that they have identified a new pathway in the brain that plays a critical role in signaling hypoglycemia. And they add that it's a solid target for drug researchers working in the blockbuster field.
Shanghai's Hua Medicine hauled in a $25 million B round to advance its work on a new treatment for diabetes, bringing in investors from the U.S. and China as it moves toward late-stage development.
Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.